CXCL9 and cervical cancer: found that imiquimod, a toll‐like receptor 7 agonist, induced local expression of CXCL9 and CXCL10 leading to CXCR3+ CD8+ CTL accumulation in the cervicovaginal tract, and enhanced potent antitumor efficacy in the orthotropic cervical cancer model when combined with intramuscular CRT/E7 vaccination 111.